133 related articles for article (PubMed ID: 33806232)
1. OTX015 Epi-Drug Exerts Antitumor Effects in Ovarian Cancer Cells by Blocking GNL3-Mediated Radioresistance Mechanisms: Cellular, Molecular and Computational Evidence.
Megiorni F; Camero S; Pontecorvi P; Camicia L; Marampon F; Ceccarelli S; Anastasiadou E; Bernabò N; Perniola G; Pizzuti A; Benedetti Panici P; Tombolini V; Marchese C
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33806232
[TBL] [Abstract][Full Text] [Related]
2. BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells.
Camero S; Camicia L; Marampon F; Ceccarelli S; Shukla R; Mannarino O; Pizer B; Schiavetti A; Pizzuti A; Tombolini V; Marchese C; Dominici C; Megiorni F
Cancer Lett; 2020 Jun; 479():71-88. PubMed ID: 32200036
[TBL] [Abstract][Full Text] [Related]
3. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
4. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
Boi M; Gaudio E; Bonetti P; Kwee I; Bernasconi E; Tarantelli C; Rinaldi A; Testoni M; Cascione L; Ponzoni M; Mensah AA; Stathis A; Stussi G; Riveiro ME; Herait P; Inghirami G; Cvitkovic E; Zucca E; Bertoni F
Clin Cancer Res; 2015 Apr; 21(7):1628-38. PubMed ID: 25623213
[TBL] [Abstract][Full Text] [Related]
5. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
6. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.
Riveiro ME; Astorgues-Xerri L; Vazquez R; Frapolli R; Kwee I; Rinaldi A; Odore E; Rezai K; Bekradda M; Inghirami G; D'Incalci M; Noel K; Cvitkovic E; Raymond E; Bertoni F
Oncotarget; 2016 Dec; 7(51):84675-84687. PubMed ID: 27835869
[TBL] [Abstract][Full Text] [Related]
7. The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma.
Gu J; Song S; Han H; Xu H; Fan G; Qian C; Qiu Y; Zhou W; Zhuang W; Li B
Mol Pharm; 2018 Nov; 15(11):5387-5396. PubMed ID: 30339013
[TBL] [Abstract][Full Text] [Related]
8. Targeting radioresistance and replication fork stability in prostate cancer.
Li X; Baek G; Carreira S; Yuan W; Ma S; Hofstad M; Lee S; Gao Y; Bertan C; Fenor de la Maza MLD; Alluri PG; Burma S; Chen BP; Raj GV; de Bono J; Pommier Y; Mani RS
JCI Insight; 2022 May; 7(9):. PubMed ID: 35349486
[TBL] [Abstract][Full Text] [Related]
9. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models.
Servidei T; Meco D; Martini M; Battaglia A; Granitto A; Buzzonetti A; Babini G; Massimi L; Tamburrini G; Scambia G; Ruggiero A; Riccardi R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668642
[TBL] [Abstract][Full Text] [Related]
10. Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma.
Shi J; Song S; Han H; Xu H; Huang M; Qian C; Zhang X; Ouyang L; Hong Y; Zhuang W; Li B
Mol Pharm; 2018 Sep; 15(9):4139-4147. PubMed ID: 30048594
[TBL] [Abstract][Full Text] [Related]
11. The Bromodomain and Extra-Terminal Protein Inhibitor OTX015 Suppresses T Helper Cell Proliferation and Differentiation.
Hu X; Schewitz-Bowers LP; Lait PJP; Copland DA; Stimpson ML; Li JJ; Liu Y; Dick AD; Lee RWJ; Wei L
Curr Mol Med; 2018; 18(9):594-601. PubMed ID: 30683020
[TBL] [Abstract][Full Text] [Related]
12. The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma.
Yu B; Liu L; Cai F; Peng Y; Tang X; Zeng D; Li T; Zhang F; Liang Y; Yuan X; Li J; Dai Z; Liao Q; Lv XB
Cancer Cell Int; 2022 Feb; 22(1):64. PubMed ID: 35135529
[TBL] [Abstract][Full Text] [Related]
13. Quinacrine Induces Nucleolar Stress in Treatment-Refractory Ovarian Cancer Cell Lines.
Oien DB; Ray U; Pathoulas CL; Jin L; Thirusangu P; Jung D; Kumka JE; Xiao Y; Sarkar Bhattacharya S; Montoya D; Chien J; Shridhar V
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572872
[TBL] [Abstract][Full Text] [Related]
14. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Gaudio E; Tarantelli C; Ponzoni M; Odore E; Rezai K; Bernasconi E; Cascione L; Rinaldi A; Stathis A; Riveiro E; Cvitkovic E; Zucca E; Bertoni F
Oncotarget; 2016 Sep; 7(36):58142-58147. PubMed ID: 27494885
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Berthon C; Raffoux E; Thomas X; Vey N; Gomez-Roca C; Yee K; Taussig DC; Rezai K; Roumier C; Herait P; Kahatt C; Quesnel B; Michallet M; Recher C; Lokiec F; Preudhomme C; Dombret H
Lancet Haematol; 2016 Apr; 3(4):e186-95. PubMed ID: 27063977
[TBL] [Abstract][Full Text] [Related]
17. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
18. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.
Gayle SS; Sahni JM; Webb BM; Weber-Bonk KL; Shively MS; Spina R; Bar EE; Summers MK; Keri RA
J Biol Chem; 2019 Jan; 294(3):875-886. PubMed ID: 30482844
[TBL] [Abstract][Full Text] [Related]
19. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
[No Abstract] [Full Text] [Related]
20. The BET bromodomain inhibitor i-BET151 impairs ovarian cancer metastasis and improves antitumor immunity.
Liu A; Fan D; Wang Y
Cell Tissue Res; 2018 Dec; 374(3):577-585. PubMed ID: 30182276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
